Top Story

FDA grants priority review to Blincyto for expanded ALL indication

March 30, 2017

The FDA granted priority review to blinatumomab to expand its indication to include all patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to the drug’s manufacturer.

The application also supports the conversion of the agent’s accelerated approval to full approval based on OS data from the phase 3 TOWER study.

Phase 2b study of iobenguane I 131 shows promise for rare neuroendocrine tumors

March 30, 2017
The registrational phase 2b trial designed to evaluate iobenguane I 131 injection for the treatment of malignant and recurrent pheochromocytoma or paraganglioma met its…
In the Journals PlusPerspective

PTC recurrence similar after hemithyroidectomy, thyroidectomy

March 30, 2017
Researchers observed no substantial difference in papillary thyroid carcinoma recurrence rate over 7 years of follow-up between adults who underwent hemithyroidectomy…
Meeting NewsVideo

VIDEO: Effective therapies needed for uveal melanoma

March 30, 2017
NEW YORK — Some clinical trials evaluating standard melanoma immunotherapies have been disappointing for metastatic uveal melanoma, Alexander Shoushtari, MD,

AMA, Mayo Clinic working to create ‘medical school of the future’

March 29, 2017
The AMA and the Mayo Clinic recently convened its 32-school Accelerating Change in Medical Education Consortium to develop innovative ideas regarding physician training…
More News Headlines »

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
Meeting News

VIDEO: New immune targets may improve advanced melanoma outcomes

March 25, 2017
More »
HEMONC TODAY Melanoma and Cutaneous Malignancies

HEMONC TODAY Melanoma and Cutaneous Malignancies


Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today